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S U M M A R Y
The clinical and economic burden of adult community-acquired pneumonia (CAP) in Latin America is not
well known. We conducted a literature review to describe the etiology, incidence, hospitalization,
morbidity and mortality, antibiotic resistance, costs associated with care, and the potential beneﬁts of
pneumococcal vaccination in the reduction of adult CAP in Latin America. Data that were published
during the period from January 1970 through August 2008 were identiﬁed via the Web sites and
databases of the Pan American Health Organization, Latin American health agencies, and the US National
Institutes of Health, National Library of Medicine (MEDLINE). Streptococcus pneumoniaewas identiﬁed as
the most common pathogen, accounting for up to 35% of CAP cases. The mean rate of CAP due to
penicillin-resistant S. pneumoniaewas 39%. The mortality in Latin America due to lower respiratory tract
infections has been reported to be 6%, compared with 4% in developed regions, and CAP was the third
most frequent cause of death in adults in 31 Latin American countries in 2001–2003. Although S.
pneumoniae caused the majority of CAP, similar to other regions of the world, mortality due to CAP in
Latin America was substantially greater than that in developed countries. This review demonstrates the
need to facilitate standardized surveillance and reporting systems to monitor the burden of CAP and to
implement prevention strategies to decrease the clinical and economic burden of CAP in Latin American
adults.
 2010 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Lower respiratory tract infections (LRTIs), which include
community-acquired pneumonia (CAP), are a leading cause of
mortality worldwide, causing 1.6 million deaths annually in adults
aged >59 years.1 Streptococcus pneumoniae is the most common
pathogen implicated in CAP. In developed regions of the world,
LRTIs have been reported to account for 4% of overall deaths, while
in Latin America, mortality due to LRTIs has been reported as 6%.2
LRTIs in persons aged 65 years were the third most frequent
cause of death in 31 Latin American countries during the period
2001 to 2003.3 In comparison, pneumoniawas found to be only the
eighth leading cause of death in the USA.4
In aging adults, the burden of CAP is of even greater concern
when considering that the number of persons aged >60 years
globally is projected to triple, from 673 million in 2005 to 2 billion
by 2050. This will be most apparent in developing regions of the
world, where this age group is projected to increase from 64%
(2005) to 80% (2050) of the total population. The 50 least
developed countries will realize a more than 200% increase in* Corresponding author. Tel.: +58 212 551 7889; fax: +58 212 552 0626.
E-mail address: risturiz7@hotmail.com (R.E. Isturiz).
1201-9712/$36.00 – see front matter  2010 Published by Elsevier Ltd on behalf of In
doi:10.1016/j.ijid.2010.02.2262their populations, from 0.8 billion in 2007 to 1.7 billion by 2050,
compared with developed regions, which are projected to remain
stable at a population of 1.2 billion.5
CAP poses a considerable health problem worldwide and is
responsible for a substantial clinical and economic burden and the
utilization of health care resources. This review examines the
etiology, incidence, hospitalization, morbidity and mortality,
antibiotic resistance, costs associated with care, and the potential
beneﬁts of pneumococcal vaccination in the reduction of CAP in
Latin American adults.
2. Methods
A review of the scientiﬁc literature using the US National
Institutes of Health, National Library of Medicine (MEDLINE)
database was conducted to ascertain the clinical and economic
burden of CAP among adults in Latin America. A broad search
strategy employing the MeSH (medical subject heading) major
topic ‘pneumonia’ was used to ensure the initial capture of all
relevant publications published during the period January 1970
through August 2008. To further identify potentially relevant data,
the Boolean operator ‘AND’ was then used with each of these
additional search terms: community acquired, hospital acquired,
health care associated, and ventilator associated. Variations ofternational Society for Infectious Diseases.
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identify adult subjects using age delimiters of adult, adult disease,
adulthood, and aged. Finally, the search results were ﬁltered to
include only those countries identiﬁed by the United Nations as
composing the geographic region of Latin America and the
Caribbean.6
The search was limited to primary articles focusing on the
epidemiology, etiology, hospitalization, morbidity and mortality,
antibiotic resistance, and clinical and economic impact of CAP in
adults in Latin America. Additional references were identiﬁed
through review of the bibliographies of retrieved articles. Although
the search period began with 1970, no relevant primary articles
regarding adult CAP in Latin America prior to 1997were identiﬁed.
There were no language restrictions.
Supplemental sources of data were identiﬁed via Web sites of
the US Census International Database, the Pan American Health
Organization, and 12 Latin American health agencies (Appendix).
2.1. Inclusion criteria
Primary articles that focused on the etiology, mortality,
antibiotic resistance, and clinical and economic burden of CAP
in adults in Latin America were included in this review. Studies
that included data on persons aged < 17 years were included only
if the data between adults and children were separated; only data
from adults were included in this review.
2.2. Exclusion criteria
Speciﬁc exclusions were review articles, articles that reported
solely on persons aged <17 years, and geographic regions other
than Latin America.
3. Results
3.1. Etiology
In a database derived by the Community-Acquired Pneumonia
Organization in 2005 to determine clinical outcomes of CAP among
adults in Latin America, S. pneumoniaewas demonstrated to be the
most common pathogen implicated in adult CAP, accounting for
35% of cases in which an organismwas identiﬁed. The secondmost
commonly identiﬁed organismwas Staphylococcus aureus in 17% of
culture-positive cases.7 Haemophilus inﬂuenzae was also an
important cause of CAP, identiﬁed as the causative agent in
23.2% of adult pneumonia cases in the Regional System for
Vaccines II (SIREVA II) study between 2000 and 2005.8 Fifty-three
percent of patients with CAP in Latin America were treated forTable 2
Number of admissions due to pneumonia in adults aged 50 years admitted to hospit
Age (years) 2000 2001 2002 200
50–59 50 211 45 445 40 616 40 0
60–69 53 230 48 564 43 368 44 5
70–79 51 265 50 200 46 890 49 9
80 39 884 40 081 38 936 42 7
Table 1
Incidence of pneumonia per 100 000 population in adults aged 50 years admitted to
Age (years) 2000 2001 2002 20
50–59 400 358 316 30
60–69 651 586 517 52
70–79 1134 1096 1013 10
80 2177 2162 2078 22atypical pathogens. The most frequently occurring atypical
pathogens were Mycoplasma pneumoniae (13%), Chlamydia pneu-
moniae (6%), and Legionella pneumophila (3%).9 In Argentina and
Chile, viruses were the second most common pathogens. Parain-
ﬂuenza virus types 1–3, inﬂuenza virus types A and B, adeno-
viruses, and respiratory syncytial virus caused approximately 6–
26% of CAP.10,11 In a multicenter clinical trial conducted in ﬁve
Latin American countries (Argentina, Brazil, Chile, Mexico, and
Uruguay), S. pneumoniae was detected in 40% of positive sputum
cultures and M. pneumoniae was detected in 16% of patients.12
Mixed organisms accounted for 8.6% of CAP infections.
3.2. Incidence
The incidence of pneumonia in the Latin American region is
substantial, however pneumonia is generally not considered to be
a reportable disease, and only estimations of the number of annual
cases have been made. In countries with the most available data,
120 000 annual cases (Argentina),13 170 000 annual cases (Chile),14
and 1 920 000 annual cases (Brazil)15,16 have been estimated.
Detailed incidence rates for Brazilian adults aged 50 years
hospitalized with CAP during the period 2000 to 2007 have been
reported.17 These data showed that hospitalization for CAP
decreased 25.3% for persons aged 50–59 years (400–299 per 100
000 population) and 19.5% for persons aged 60–69 years (651–524
per 100 000 population). In older age groups incidence rates
increased 5.2% for persons aged 70–79 years (1134–1193 per 100
000 population) and 33.0% for persons aged80 years (2177–2895
per 100 000 population) (Table 1).17
3.3. Hospitalizations
The most detailed available hospitalization data was also for
Brazil. During the 2000 to 2007 period, 1 524 376 hospital
admissions for pneumonia for adults aged50 yearswere reported
in Brazil (Table 2).17 As to be expected with the decreased
incidence rates previously shown, the number of hospitalizations
decreased 17% for persons aged 50–59 years (50 000–41 480) and
11.4% for persons aged 60–69 years (53 230–47 154). The number
of hospitalizations increased 15.3% for persons aged 70–79 years
(51 265–59 095) and 45.3% for persons aged80 years (39 884–57
936). CAP was the second most frequent reason for hospital
admission in Brazil in 2003.18
A prospective study of 84 patients in ﬁve Latin American
countries (Argentina, Brazil, Chile, Mexico, and Uruguay) showed
that 50–52.8% of CAP patients were admitted to the hospital.12,15,16
This high rate of hospitalization increases the economic burden of
CAP through utilization of more expensive health care resourcesal in Brazil from 2000 to 200717
3 2004 2005 2006 2007
84 43 431 39 940 40 960 41 480
56 51 310 46 226 46 812 47 154
35 58 693 53 989 56 305 59 095
13 51 949 50 011 53 107 57 936
hospital in Brazil from 2000 to 200717
03 2004 2005 2006 2007
9 330 296 299 299
6 599 526 526 524
67 1241 1115 1150 1193
56 2716 2556 2684 2895
Table 3
Percentage susceptibility of Streptococcus pneumoniae to penicillin and ceftriaxone
in 2005 (age >15 years)26
Country Penicillin Ceftriaxone
No. of
isolates
S I R S I R
Brazil
15–60 years 261 79.7 16.5 3.8 98.1 1.9 0.0
>60 years 60 88.4 8.3 3.3 98.3 1.7 0.0
Chile
15–60 years 149 93.3 5.4 1.3 99.3 0.7 0.0
>60 years 135 89.6 8.9 1.5 100.0 0.0 0.0
Colombia
15–60 years 97 76.3 9.3 14.4 87.6 10.3 2.1
>60 years 42 81.0 7.1 11.9 85.7 14.3 0.0
Cuba
15–60 years 11 81.8 9.1 9.1 90.9 9.1 0.0
>60 years 49 83.7 12.2 4.1 96.0 2.0 2.0
Mexico
15–60 years 13 46.1 7.7 46.2 69.2 30.8 0.0
>60 years 13 46.1 7.7 46.2 76.9 15.4 7.7
S, sensitive (MIC 0.06mg/ml); I, intermediate resistance (MIC 0.12–1mg/ml); R,
high resistance (MIC 2mg/ml); MIC, minimum inhibitory concentration.
[(Figure_1)TD$FIG]
Figure 1.Distribution by percentage of themost common serotypes of Streptococcus
pneumoniae in adults by age group—SIREVA II, 2000–2005.8
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are treated as outpatients.15 In a retrospective study in Argentina
that assessed 436 patients admitted to 12 hospitals, 30% were
admitted to the intensive care unit (ICU).19
3.4. Mortality
In Argentina, CAP-related mortality averaged 13.3% in two
studies of hospitalized patients (1998–1999 and 2000–2001).13 In
Brazil, pneumonia was the leading cause of death among
respiratory diseases at all ages and the fourth leading cause of
death in adults, causing 26 394 deaths in 1996.15 Mortality due to
pneumonia increased 13.7% to 30 000 deaths in 2001; 17 700 of
these (59%) were in adults aged 65 years. Also in Brazil, hospital
mortality rates increased between 1998 (2.0%) and 2003 (2.9%).18
In Chile, CAP mortality among adults aged 20–64 years was 14.8
per 100 000 population20 and was 17 times higher at 258.8 per
100 000 population for adults aged 65 years.3 For hospitalized
patients aged 65 years, mortality ranged from 7.6–9.8% (in-
hospital) to 12.4–13.1% (30-day follow-up),21,22 with an ICU
mortality of 20%.21
3.5. Antibiotic resistance
Penicillin-resistant S. pneumoniae is an increasingly important
pathogen worldwide. An independent study conducted in Brazil
revealed substantial increases in penicillin resistance in strains of
S. pneumoniae – a 300% increase in high resistance and a 61%
increase in intermediate resistance from 1998 to 2003.23
Two major surveillance studies of S. pneumoniae resistance
conducted in Latin America are the SENTRY Antimicrobial
Surveillance Program and the SIREVA II Surveillance Program.
The SENTRY Antimicrobial Surveillance Programwas conducted in
seven countries (Argentina, Brazil, Chile, Colombia, Mexico,
Uruguay, and Venezuela) from 1997 to 2001, during which 1561
isolates were collected from subjects with CAP for assessment of
antimicrobial resistance rates for S. pneumoniae. The majority of
the isolates (87%) were recovered from Argentina, Brazil, and
Chile,24 and most were collected from the respiratory tract (77%).
Almost half of the isolates were obtained from middle-aged and
older adult patients – 24% of the subjects were in the group aged
41–64 years and 24% were aged 65 years. Rates of penicillin
resistance were 15.5% in adults aged 41–60 years and 11.3% in
those aged65 years and, along with erythromycin resistance, did
not vary signiﬁcantly over the years studied. For all age groups,
penicillin resistance ranged from 2.8% in Venezuela to 25% in
Mexico, demonstrating a marked variability across the region.24
The mean rate of penicillin-resistant S. pneumoniae was 39%.25
The World Health Organization (WHO) and the Pan American
Health Organization jointly conducted the SIREVA II S. pneumoniae
Surveillance Program through a network of 20 participating
hospitals and sentinel laboratories in Latin American countries.
The program gathered data on the distribution of serotypes and
susceptibility of S. pneumoniae between 2000 and 2005.26 Results
on S. pneumoniae susceptibilities to penicillin and ceftriaxone in
2005 from countries who collected at least 60 isolates from adults
are shown in Table 3.26 Resistance rates to chloramphenicol,
erythromycin, and trimethoprim–sulfamethoxazole (SXT) were
also evaluated during the SIREVA II study period. Where reported,
S. pneumoniae generally remained susceptible, in adults, to
chloramphenicol and erythromycin.26 However, high levels of
resistance to SXT were observed for the adult population from
2000 to 2005: 33–54.5% in Brazil, 11.2–30.2% in Chile, 19.6–35.8%
in Columbia, 14.3–40.0% in adults aged >60 years in Cuba, and
23.5–55.6% inMexico, where resistance by S. pneumoniae to SXT in
persons aged >60 years almost doubled from 2000 to 2005 (from23.5–53.8%).26 Resistance to erythromycinwas also high inMexico
at 10.0–46.2% and more than doubled during the surveillance
period. It is also noteworthy that although the sample sizes were
small (n = 13 for each age group), 30.8% of isolates retrieved from
CAP patients aged 15–60 years and 15.4% from patients aged >60
years in Mexico showed intermediate resistance to ceftriaxone in
2005.26 These data underscore the importance of continued
surveillance and judicious use of antibiotics in treating pneumo-
coccal infections and the need to implement adult vaccination
programs to reduce the rate of antibiotic use.
The SIREVA II initiative also studied the distribution of S.
pneumoniae serotypes in Latin America and the Caribbean.
Serotypes 1, 3, and 14 were responsible for the highest proportion
of pneumococcal disease in adults (Figure 1).8
4. Discussion
The incidence of CAP and prevalence of pathogens in CAP vary
throughout Latin America. CAP in the Latin American region is not
subject to epidemiological monitoring, and there are minimal
reliable data on its incidence and etiology among adults. Further,
the literature on CAP in Latin America has focused on pediatric
populations, and the impact of CAP in adults may be under-
recognized and under-reported.
Data on CAP among adults in Latin America have primarily been
reported from those countries that are more developed and have
greater ﬁnancial resources – Argentina, Brazil, Chile, and Mexico.
Data on CAP among adults in Latin America from other countries
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Further, the etiology of CAP is difﬁcult to assess from published
studies in Latin America because of variations in screening,
variations in the inclusion or exclusion criteria for age and co-
morbidities, differences in methodology, and the use of antibiotics
prior to culture.
Microbiology testing is not routinely performed in clinical
practice, and any evidence that it has clinical value is sparse in the
literature.10 Obtaining microbial specimens to determine the
etiological agent(s) involved in CAP becomes a major challenge in
aged patients as more than 50% of these patients do not have a
productive cough with expectoration at the time of diagnosis.20
Delays in initiating antibiotic treatment are linked to a greater risk
of complications and death, particularly in those requiring
hospitalization. Although empiric therapy should be rapidly
initiated, microbiologic studies should be conducted to identify
the causal agent and facilitate speciﬁc antimicrobial treatment for
patients hospitalized with CAP and those who are at increased risk
for death.27 There is no consensus in Latin America regarding the
use of antimicrobial agents that cover atypical pathogens in the
initial treatment of patients hospitalized with CAP. Only 53% of
hospitalized CAP patients in Latin America received empiric
therapy for typical and atypical pathogens in accordance with
North American guidelines,27,28 compared with 91% of North
American inpatients.9
The emerging resistance among the causative pathogens of CAP
adds to the economic burden of this disease bymaking it necessary
to alter established therapeutic regimens. Penicillin resistance is
often associated with cross-resistance to other antibiotics and
multidrug-resistant strains may create a demand for newer
antimicrobials, which are often more costly than existing
therapies.
In January 2008, the Clinical and Laboratory Standards Institute
revised the penicillin minimum inhibitory concentration (MIC)
breakpoints for infections due to S. pneumoniae.29 The susceptibil-
ity breakpoints for penicillin administered parenterally for non-
meningeal infections due to S. pneumoniae have been increased as
follows: susceptible, 2 mg/ml; intermediate, 4 mg/ml; and
resistant, 8 mg/ml. The breakpoints for penicillin-susceptible
and resistant S. pneumoniae meningeal infections due to S.
pneumoniae are 0.06 mg/ml and 0.12mg/ml, respectively. The
impact of applying the new breakpoints to the data derived from
the SENTRY Antimicrobial Surveillance Program was demonstrat-
ed as follows: using the prior MIC breakpoint of0.06 mg/ml, only
68% of S. pneumoniae isolates would be considered susceptible to
penicillin, but according to the new breakpoint of2mg/ml, 93% of
the isolates would be susceptible.30 Therefore, if data from the
studies described in this review utilized the new breakpoints, the
percentage of penicillin-resistant S. pneumoniae isolates would
likely be lower and similar to the proportion of isolates susceptible
to ceftriaxone (MICs susceptible, 1 mg/ml; 2 intermediate , mg/
ml; and resistant, 4mg/ml) administered parenterally for non-
meningeal infections (96%).
Although CAP has a major economic impact on health care
systems worldwide, there are only limited data regarding this
burden in Latin America. Moreover, there is no clear information
contained in these studies on how the treatment of pneumococcal
disease is calculated, and what is included in cost estimates. The
data from one population is not applicable to other populations,
and are not representative of the true cost of pneumococcal
disease.31
Pneumococcal vaccines are effective in reducing rates of
invasive pneumococcal disease (IPD) and CAP due to S. pneumo-
niae,32 and substantial preventive beneﬁts can be achieved
through their incorporation into national immunization programs
(NIPs).33 A polysaccharide pneumococcal vaccination is recom-mended by the Advisory Committee on Immunization Practices
(ACIP) for all persons aged 65 years and persons aged <65 years
who are at high risk for pneumococcal infections.34 The H.
inﬂuenzae b conjugate vaccine is implemented nearly universally
throughout Latin America,35 but vaccination for S. pneumoniae,
which causes more invasive and noninvasive diseases, has not
been widely implemented.36 In the USA, nearly universal
vaccination of children with the seven-valent pneumococcal
conjugate vaccine (PCV7) resulted in an 18% decrease in the
incidence of IPD in persons aged 65 years and reduced the
incidence of IPD caused by antibiotic-resistant strains by 35%.37
PCV7 vaccination diminished levels of pneumococcal disease in
both adults and unvaccinated children in addition to vaccinated
children. In the USA in 2003, compared with 1998–1999, twice as
many IPD cases were prevented through indirect effects via
interruption of pneumococcal transmission than through the
direct effect of vaccinating children.38 Despite these substantial
indirect effects, many adults remain at risk for pneumococcal
disease, and directly vaccinating adults within the context of a
vaccine program is a sound public health strategy.
5. Conclusions
S. pneumoniae remains the leading cause of CAP and is
associated with a high incidence of mortality in Latin American
adults. As populations age, there is an increase in co-morbidities,
increased susceptibility to infection, and a greater risk for
hospitalization. Temporal variations in endemic pathogens and
increasing antibiotic resistance diminish the therapeutic efﬁcacy
of existing treatment regimens, thus leading to a need for newer,
more expensive antimicrobial agents.
Limited information on the epidemiology and etiology of CAP in
Latin American adults makes it difﬁcult to gain a perspective
regarding the evolution of the disease in this region. Comprehen-
sive surveillance and standardized reporting systems such as the
SENTRY and SIREVA II programs will facilitate the monitoring of
emerging resistance patterns, guide clinicians in the choice of
appropriate treatment options, and improve outcomes for patients
with CAP.
The lack of data on adult pneumococcal disease in this region
may be a factor in the limited use of pneumococcal vaccination
among adults. Incorporation of pneumococcal conjugate vaccines
into NIPs will help the vaccine reach the most vulnerable
populations and should be expanded to include adults.
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Appendix A. Appendix
Supplemental data sources
Pan American Health Organization (www.paho.org)
US Census International Database (http://www.census.gov/ipc/
www/idb/index.html)
Latin American health agencies:
R.E. Isturiz et al. / International Journal of Infectious Diseases 14 (2010) e852–e856e856Argentina: National Administration of Foods, Drugs and
Medical Technology (http://www.anmat.gov.ar)
Bolivia: Ministry of Health and Welfare (http://
www.sns.gov.bo)
Brazil: Ministry of Health (http://www.saude.gov.br)
Chile: Health Ministry of Chile, Institute of Public Health
(http://www.ispch.cl)
Colombia: Ministry of Health (http://www.minsalud.gov.co)
Colombia: Instituto Nacional de Vigilancia de Medicamentos y
Alimentos (INVIMA) (http://www.sinpro.gov.co/invima)
Costa Rica: Ministry of Health (http://www.netsalud.sa.cr/ms)
Ecuador: Ministry of Public Health (http://www.msp.gov.ec)
Honduras: Ministry of Health (http://www.paho-who.hn/ssa-
lud)
Mexico: Ministry of Health (http://www.ssa.gob.mx)
Peru: Ministry of Health (http://wwww.digesa.sld.pe)
Uruguay: Ministry of Public Health (http://www.msp.gub.uy).
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